mTOR即雷帕霉素靶蛋白,含有两种复合体,分别为mTORC1和mTORC2。因其是重要的真核细胞信号,调节细胞的生长、凋亡、自噬等,mTOR成为肿瘤治疗的新靶点,mTOR抑制剂已应用于实体瘤、器官移植等疾病研究及治疗中。
图1 mTORC1和mTORC2 [1]
mTOR抑制剂选择见下表:
注:1、IC50: 全称half maximal inhibitory concentration,指物质发挥其最大抑制效果的一半时的浓度。 2、★代表抑制作用的强度,抑制作用越强,★ 越多。 3、√表示该化合物对相应的亚型有抑制作用,但暂时无相关数据。
- Kathryn G. Foster, Diane C. Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony. J Biol Chem. 2010 May 7; 285(19): 14071–14077.
Description:
a novel ATP-competitive inhibitor of mTOR kinase with an IC50 of 0.8 nM
Description:
a selective and ATP-competitive mTOR inhibitor with an IC50 of 8 nM,PP242 inhibits both mTORC1 and mTORC2 with IC50s of 30 nM and 58 nM
Description:
a novel mTOR inhibitor
Description:
a potent and selective mTOR inhibitor
Description:
a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC50s of 0.4 nM, 5.4 nM and 1.6 nM, respectively. PKI-587 is equally effective in both complexes of mTOR, mTORC1 and mTORC2
Description:
a novel potent inhibitor of both the mTORC1 and mTORC2
Description:
a potent mTOR inhibitor that binds to FKBP-12 to generate an immunosuppressive complex
Description:
an inhibitor of mTOR with an IC50 of 1.76 μM
Description:
a potent PI3K/Akt and mTOR inhibitor